These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 33059733)

  • 1. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
    Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
    JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
    Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
    McDaniel NK; Iida M; Nickel KP; Longhurst CA; Fischbach SR; Rodems TS; Kranjac CA; Bo AY; Luo Q; Gallagher MM; Welke NB; Mitchell KR; Schulz AE; Eckers JC; Hu R; Salgia R; Hong S; Bruce JY; Kimple RJ; Wheeler DL
    Clin Cancer Res; 2020 Aug; 26(16):4349-4359. PubMed ID: 32439698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
    Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixidó C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
    Cancer Cell; 2015 Apr; 27(4):533-46. PubMed ID: 25873175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL mediates resistance to cetuximab therapy.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
    Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
    Al Kafri N; Hafizi S
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.
    Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T
    Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
    Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Skinner HD; Giri U; Yang LP; Kumar M; Liu Y; Story MD; Pickering CR; Byers LA; Williams MD; Wang J; Shen L; Yoo SY; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
    Clin Cancer Res; 2017 Jun; 23(11):2713-2722. PubMed ID: 28476872
    [No Abstract]   [Full Text] [Related]  

  • 18. β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models.
    Korovina I; Elser M; Borodins O; Seifert M; Willers H; Cordes N
    Biomed Pharmacother; 2024 Feb; 171():116217. PubMed ID: 38286037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
    Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
    Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.